The authors of each study demonstrated proof of principle that STING signaling can be augmented to boost in situ vaccination effects of RT: either by blocking cathepsin-mediated degradation of active STING signaling complexes in DCs (10), or by blocking the suppressive function of HO-1 on both cGAS and STING in cancer cells (11) (Figure 1). The gene discussed is HMOX1; the disease is cancer.